Payment overview · 2025
General Payments
$677.15
39 reported records · 16 companies
Healthcare provider profile · identity verified
Richard Bennett, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SAINT GEORGE, UT · NPI 1407871510
Verified facts
What the public records show
CMS Open Payments records show Richard Bennett, MD received $677.15 in general payments during 2025 across 39 reported records.
ABBVIE INC. accounted for 39.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Synthroid by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 250 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 121 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 211 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 221 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 250 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Paxlovid by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SOLIQUA 100/33 as an associated drug or biological on 43 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Soliqua 100-33 by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $270.01 | 39.9% | 18 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $53.75 | 7.9% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $53.35 | 7.9% | 3 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $44.31 | 6.5% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $35.63 | 5.3% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $25.49 | 3.8% | 1 | 2025 |
| RGH Enterprises LLC | Unresolved — no canonical attribution shown | $24.00 | 3.5% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $22.91 | 3.4% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $22.57 | 3.3% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $21.14 | 3.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $18.97 | 2.8% | 1 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $18.46 | 2.7% | 1 | 2025 |
| Acella Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $18.36 | 2.7% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $17.76 | 2.6% | 1 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.68 | 2.3% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $14.76 | 2.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $677.15 | 39 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $203.25 | 13 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $186.00 | 12 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $48.55 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $31.93 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $31.93 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $31.77 | 2 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $25.49 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $23.03 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $22.91 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $22.57 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $22.57 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $21.98 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $21.42 | 1 | 2025 |
Source payment records
|
|||||
| VOWST Normalized: vowst |
Biological | Aimmune Therapeutics, Inc. | $21.28 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $21.14 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $18.97 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $18.94 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $18.94 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $18.94 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $18.46 | 1 | 2025 |
Source payment records
|
|||||
| NP Thyroid 60 Normalized: np thyroid 60 |
Drug | Acella Pharmaceuticals, LLC | $18.36 | 1 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $17.76 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $16.69 | 1 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $15.68 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $14.76 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 250 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 211 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 221 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
54 | 17 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
250 | 68 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
121 | 31 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
211 | 39 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
51 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
221 | 53 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
250 | 68 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
38 | 38 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | SOLIQUA 100/33 open payments reported associated product |
CMS Open Payments — General Payments 43 supporting records · 15 recipient NPIs · example record 1233224976 |
Soliqua 100-33 · 2024 Exact normalized brand match · 1 Part D row |
71 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1325 | 386 |
| Losartan Potassium | Losartan Potassium | 1100 | 339 |
| Atorvastatin Calcium | Atorvastatin Calcium | 835 | 260 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 790 | 254 |
| Amlodipine Besylate | Amlodipine Besylate | 574 | 175 |
| Omeprazole | Omeprazole | 549 | 166 |
| Tamsulosin Hcl | Tamsulosin Hcl | 444 | 149 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 420 | 131 |
| Gabapentin | Gabapentin | 394 | 129 |
| Metformin Hcl | Metformin Hcl | 382 | 122 |
| Metoprolol Succinate | Metoprolol Succinate | 367 | 112 |
| Pantoprazole Sodium | Pantoprazole Sodium | 360 | 119 |
| Quetiapine Fumarate | Quetiapine Fumarate | 357 | 94 |
| Alendronate Sodium | Alendronate Sodium | 324 | 95 |
| Potassium Chloride | Potassium Chloride | 312 | 111 |
| Lisinopril | Lisinopril | 284 | 92 |
| Trazodone Hcl | Trazodone Hcl | 283 | 83 |
| Simvastatin | Simvastatin | 282 | 80 |
| Eliquis | Apixaban | 250 | 68 |
| Allopurinol | Allopurinol | 242 | 76 |
| Furosemide | Furosemide | 225 | 80 |
| Ozempic | Semaglutide | 221 | 53 |
| Tramadol Hcl | Tramadol Hcl | 220 | 65 |
| Mounjaro | Tirzepatide | 211 | 39 |
| Spironolactone | Spironolactone | 209 | 69 |
| Hydrochlorothiazide | Hydrochlorothiazide | 201 | 77 |
| Carvedilol | Carvedilol | 200 | 56 |
| Escitalopram Oxalate | Escitalopram Oxalate | 177 | 56 |
| Finasteride | Finasteride | 159 | 50 |
| Pravastatin Sodium | Pravastatin Sodium | 156 | 43 |
| Duloxetine Hcl | Duloxetine Hcl | 155 | 51 |
| Montelukast Sodium | Montelukast Sodium | 152 | 45 |
| Sertraline Hcl | Sertraline Hcl | 148 | 46 |
| Meloxicam | Meloxicam | 124 | 44 |
| Jardiance | Empagliflozin | 121 | 31 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 119 | 105 |
| Pioglitazone Hcl | Pioglitazone Hcl | 118 | 38 |
| Citalopram Hbr | Citalopram Hydrobromide | 117 | 33 |
| Estradiol | Estradiol | 115 | 51 |
| Famotidine | Famotidine | 115 | 32 |
| Farxiga | Dapagliflozin Propanediol | 115 | 34 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 111 | 91 |
| Nebivolol Hcl | Nebivolol Hcl | 111 | 35 |
| Metformin Hcl Er | Metformin Hcl | 110 | 33 |
| Pregabalin | Pregabalin | 108 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 107 | 38 |
| Oxybutynin Chloride | Oxybutynin Chloride | 107 | 40 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 105 | 46 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 105 | 33 |
| Lorazepam | Lorazepam | 105 | 29 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 104 | 35 |
| Ropinirole Hcl | Ropinirole Hcl | 96 | 23 |
| Valacyclovir | Valacyclovir Hcl | 93 | 36 |
| Celecoxib | Celecoxib | 92 | 35 |
| Methenamine Hippurate | Methenamine Hippurate | 91 | 33 |
| Azithromycin | Azithromycin | 89 | 80 |
| Fluoxetine Hcl | Fluoxetine Hcl | 88 | 27 |
| Zolpidem Tartrate | Zolpidem Tartrate | 88 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 84 | 31 |
| Bupropion Xl | Bupropion Hcl | 81 | 24 |
| Ezetimibe | Ezetimibe | 81 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 72 | 29 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 71 | 20 |
| Myrbetriq | Mirabegron | 70 | 17 |
| Prednisone | Prednisone | 68 | 37 |
| Xarelto | Rivaroxaban | 68 | 22 |
| Donepezil Hcl | Donepezil Hcl | 67 | 23 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 67 | 20 |
| Memantine Hcl | Memantine Hcl | 64 | 23 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 62 | 19 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 60 | 24 |
| Alprazolam | Alprazolam | 59 | 22 |
| Atenolol | Atenolol | 57 | 19 |
| Propranolol Hcl | Propranolol Hcl | 55 | 17 |
| Synthroid | Levothyroxine Sodium | 54 | 17 |
| Buspirone Hcl | Buspirone Hcl | 53 | 13 |
| Ibuprofen | Ibuprofen | 51 | 24 |
| Trulicity | Dulaglutide | 51 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 50 | 19 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 49 | 31 |
| Clonazepam | Clonazepam | 47 | 16 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 47 | 14 |
| Fluconazole | Fluconazole | 44 | 17 |
| Humalog Kwikpen U-100 | Insulin Lispro | 44 | 16 |
| Warfarin Sodium | Warfarin Sodium | 44 | 13 |
| Irbesartan | Irbesartan | 43 | 12 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 43 | 37 |
| Raloxifene Hcl | Raloxifene Hcl | 43 | 16 |
| Lovastatin | Lovastatin | 42 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 42 | 25 |
| Symbicort | Budesonide/Formoterol Fumarate | 41 | 13 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 38 | 13 |
| Paxlovid | Nirmatrelvir/Ritonavir | 38 | 38 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 38 | 17 |
| Methocarbamol | Methocarbamol | 37 | 14 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 36 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 35 | 11 |
| Potassium Citrate Er | Potassium Citrate | 35 | 15 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 34 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 33 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 33 | 13 |
| Chlorthalidone | Chlorthalidone | 32 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 32 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 32 | 30 |
| Naproxen | Naproxen | 31 | 11 |
| Testosterone Cypionate | Testosterone Cypionate | 31 | 15 |
| Aripiprazole | Aripiprazole | 30 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 30 | 14 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 30 | suppressed |
| Valsartan | Valsartan | 30 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 29 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 29 | suppressed |
| Acyclovir | Acyclovir | 28 | 11 |
| Bupropion Hcl | Bupropion Hcl | 28 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 28 | suppressed |
| Hydrocortisone | Hydrocortisone | 27 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 27 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 26 | suppressed |
| Primidone | Primidone | 26 | suppressed |
| Cephalexin | Cephalexin | 25 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 25 | 11 |
| Nifedipine Er | Nifedipine | 24 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 24 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 23 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Glimepiride | Glimepiride | 23 | suppressed |
| Sucralfate | Sucralfate | 22 | suppressed |
| Topiramate | Topiramate | 22 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 21 | suppressed |
| Diazepam | Diazepam | 21 | suppressed |
| Lamotrigine | Lamotrigine | 21 | suppressed |
| Methimazole | Methimazole | 21 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Lansoprazole | Lansoprazole | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | 11 |
| Armour Thyroid | Thyroid,pork | 19 | suppressed |
| Baclofen | Baclofen | 19 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 19 | 14 |
| Doxepin Hcl | Doxepin Hcl | 19 | suppressed |
| Mirtazapine | Mirtazapine | 19 | suppressed |
| Novolog Flexpen | Insulin Aspart | 19 | 12 |
| Nystatin | Nystatin | 19 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 19 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 19 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 18 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 18 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 18 | suppressed |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Digoxin | Digoxin | 17 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 17 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 17 | suppressed |
| Januvia | Sitagliptin Phosphate | 17 | suppressed |
| Levemir Flexpen | Insulin Detemir | 17 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 17 | suppressed |
| Klor-Con M20 | Potassium Chloride | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | suppressed |
| Telmisartan | Telmisartan | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | 11 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 15 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 15 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Premarin | Estrogens, Conjugated | 15 | suppressed |
| Progesterone | Progesterone, Micronized | 15 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 14 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 13 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 13 | suppressed |
| Febuxostat | Febuxostat | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Sotalol | Sotalol Hcl | 13 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 12 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Dulera | Mometasone/Formoterol | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | 11 |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $677.15 · 39 records | ABBVIE INC. | ABRYSVO, CAMZYOS, CAPVAXIVE, COMIRNATY, ELIQUIS, EVENITY, KISUNLA, MOUNJARO, NP Thyroid 60, Ozempic, PREVNAR 20, PURIFIED CORTROPHIN GEL, QULIPTA, REPATHA, Rybelsus, SHINGRIX, TZIELD, Tymlos, UBRELVY, UPTRAVI, VOWST, VRAYLAR, WATCHMAN FLX, ZENPEP, ZEPBOUND | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error